Abstract
Crystallographic fragment screening is a technique for initiating drug discovery in which protein crystals are soaked or grown with high concentrations of small molecule compounds (typically MW 110–250 Da) chosen to represent fragments of potential drugs. Specific binding of these compounds to the protein is subsequently visualized in electron density maps obtained from analysis of X-ray diffraction data collected from these crystals. Theoretical and practical experience indicate that a suitably diverse library of fragment compounds containing only a few hundred compounds may be sufficient to provide a comprehensive screen of the protein target. By soaking crystals in mixtures of 3–10 compounds a fragment screen may be completed within ∼100 diffraction data sets. This data collection requirement may be met given reproducible well-diffracting protein crystals and robotic sample handling equipment at a high flux X-ray source. The leading practical issue for most crystallography laboratories that wish to launch a fragment screening project is the design and/or procurement of an appropriate fragment library. Although several off-the-shelf fragment libraries are available from chemical suppliers, the numbers, sizes, and solubility of the compounds in relatively few of these libraries are well-match to the specific needs of the crystallographic screening experiment. Informed consideration of the properties of compounds in the screening library, possibly augmented by additional filtering of available compounds with appropriate search tools, is required to design a successful experiment. The analysis of results from crystallographic fragment screening involves highly repetitive application of routine image data processing and structure refinement calculations from many very similar crystals. Efficient handling of the data applies a high-throughput structure determination methodology that conveniently packages the structure solution calculations into a single process that provides the crystallographer-analyst with ready-to-view maps for evaluating crystals for bound compounds.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Hann, M.M., Leach, A.R. and Harper, G. (2001) Molecular complexity and its impact on the probability of finding leads for drug discovery J.Chem.Inf.Comput.Sci. 41, 856–864.
Rees, D.C., Congreve, M., Murray, C.W. and Carr, R. (2004) Fragment-based lead discovery Nat. Rev. Drug Disc. 3, 660–672.
Blundell, T.L., Jhoti, H. and Abell, C. (2002) High-throughput crystallography for lead discovery in drug design Nat. Rev. Drug Disc. 1, 45–54.
Nienaber, V.L., Richardson, P.L., Klighofer, V., Bouska, J.J., Giranda, V.L. and Greer, J. (2000) Discovering novel ligands for macromolecules using X-ray crystallographic screening Nat.Biotechnol. 18, 1105–1108.
Hajduk, P.J. and Greer, J. (2007) A decade of fragment-based drug design; strategic advances and lessons learned Nat. Rev. Drug Disc. 6, 212–219.
Kuntz,I.D., Chen, K., Sharp, P.A. and Kollman, P.A. (1999) The maximal affinity of ligands Proc.Natl.Acad.Sci.U.S.A. 96, 9997–10002.
Lipinski, C.A., Lombardo, B.W. Dominy and P.J. Feeney (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Del. Rev. 23 , 3–25.
Pardridge, W.M. (2005) The Blood-brain Barrier: Bottleneck in Brain Drug Development The journal of the American Society for Experimental NeuroTherapeutics 2, 3–14.
Bosch, J., Robien, M.A., Mehlin, C., Boni, E., Riechers, A., Buckner, F.S., Van Voorhis, W.C., Myler, P.J., Worthey, E.A., DeTitta, G., Luft, J.R., Lauricella, A., Gulde, S., Anderson, L.A., Kalyuzhniy, O., Neely, H.M., Ross, J., Earnest, T.N., Soltis, M., Schoenfeld, L., Zucker, F., Merritt, E.A., Fan, E., Verlinde, C.L.M.J. and Hol, W.G.J. (2006) Using Fragment Cocktail Crystallography To Assist Inhibitor Design of Trypanosoma brucei Nucleoside 2-Deoxyribosyltransferase J.Med.Chem. 49, 5939–5946.
Congreve, M., Carr, R., Murray, C. and Jhoti, H. (2003) A ‘rule of three’ for fragment-based lead discovery? Drug Discovery Today 8, 876–877.
Hubbard, R.E., Davis, B., Chen, I. and Drysdale, M.J. (2007) The SeeDs Approach: Integrating Fragments into Drug Discovery Current Topics in Medicinal Chemistry 7, 1–13.
Hartshorn, M.J., Murray, C.W., Cleasby, A., Frederickson, M., Tickle, I.J. and Jhoti, H. (2005) Fragment-Based Lead Discovery Using X-ray Crystallography JACS 48, 403–413.
Collaborative Computational Project, Number 4 (1994) The CCP4 Suite: Programs for Protein Crystallography Acta Cryst. D50, 760–763.
Brünger, A.T., Adams, P.D., Clore, G.M., DeLano, W.L., Gros,P., Grosse-Kunstleve, R.W., Jiang, J.-S., Kuszewski, J., Nilges, M., Pannu, N.S., Read, R.J., Rice, L.M., Simonson, T. and Warren, G.L. (1998) Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination Acta Cryst. D54, 905–921.
Mooij, W.T.M., Hartshorn, M.J., Tickle, I.J., Sharff, A.J., Verdonk, M.L. and Jhoti, H. (2006) Automated Protein-Ligand Crystallo-graphy for Structure-Based Drug Design Chem. Med. Chem. 1, 827–838.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Badger, J. (2012). Crystallographic Fragment Screening. In: Tari, L. (eds) Structure-Based Drug Discovery. Methods in Molecular Biology, vol 841. Humana Press. https://doi.org/10.1007/978-1-61779-520-6_7
Download citation
DOI: https://doi.org/10.1007/978-1-61779-520-6_7
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-519-0
Online ISBN: 978-1-61779-520-6
eBook Packages: Springer Protocols